Mainz, Germany 14th June 2016 – BioNTech AG, a fully integrated biotechnology company developing individualized cancer immunotherapies is pleased to announce that it was presented with the “Emerging Star of the Year Award” at the European Mediscience Awards 2016.
Sean Marett, Chief Operating Officer of BioNTech AG said: “We are proud to receive the Emerging Star Award, which is a tremendous honor for us. In the past year BioNTech has expanded rapidly and made significant progress publishing two groundbreaking scientific papers in Nature on personalized mRNA cancer vaccines, advancing its clinical immuno-oncology pipeline, with now four products in the clinic (and two more entering this year), expanding its GMP manufacturing, signing four collaborations with international pharmaceutical companies and launching its first molecular cancer diagnostic test internationally. BioNTech’s progress supports its long term strategy of bringing its own pharmaceutical products to market. ”
The Mediscience awards are the largest annual gathering of private and publicly quoted healthcare, biotech and life science companies in Europe. The event brings together the best of European Life Sciences companies to celebrate achievement and recognise success. Each year sees attendance of over 500 quoted and private European life science companies and their corporate advisors, analysts, fund manager, commentators and peers.